The anti-OX40 monoclonal antibody rocatinlimab produced clinically meaningful improvements in adults with moderate-to-severe ...
A position paper argues that any systemic corticosteroid exposure in atopic dermatitis should trigger a transition to ...
Dupilumab significantly reduced pruritus in patients with chronic kidney disease, including those with uremic pruritus and atopic dermatitis, in a real-world study demonstrating safety and sustained ...
Nearly 50% of survey respondents living with atopic dermatitis (AD) report a severe impact on their quality of life, yet 79% ...
The FDA has expanded the indication of Incyte’s Opzelura (ruxolitinib) cream to include children aged two to 11 years with ...
The FDA approved a supplemental new drug application for ruxolitinib cream 1.5% for the short-term and noncontinuous ...
US drug developer Nektar Therapeutics saw its shares rise 9% to $55.66 following release of new data from the ongoing REZOLVE ...
Triveni Bio, Inc., a biotechnology company focused on developing innovative antibody treatments for inflammation and ...
Dr. Vince Clinical Research announces first dosing in atopic dermatitis patients with Enveda’s first-in-class investigational ...
Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback